Inhibrx Biosciences, Inc.
INBRX-106
metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Resolved
7days ago
Phase 2 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 2 trial results for INBRX-106 in metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“We plan to announce interim objective response rate (“ORR”) data from the randomized Phase 2/3 trial in head and neck squamous cell carcinoma (“HNSCC”) in combination with KEYTRUDA ® (pembrolizumab) in the second quarter of 2026;”